Following his presentation at ACR 2020, Rene Westhovens talked to us about the 52 week results of the FINCH 3 study. The phase 3 study evaluated the efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis (Clinical Trial Identifier: NCT02886728). The abstract ‘Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results’ (ABSTRACT NUMBER: 0217) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- What are the most important unmet needs in the treatment of rheumatoid arthritis (RA)? (0:39)
- What is the rationale for the use of filgotinib in this treatment setting? (3:59)
- Could you tell us a little about the FINCH 3 study? (6:06)
Disclosures: Principal Investigator and Advisor for Celltrion and also Gilead/Galapagos
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
